Transplantation in 2011: New agents, new ideas and new hope

Nature Reviews Nephrology

Volumn 8, Issue 2, 2012, Pages 74-75

  Srinivas, Titte R ^a   Kaplan, Bruce ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANTIGEN PRESENTING CELL; CORTICOSTEROID THERAPY; DESENSITIZATION; DIALYSIS; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW;

ANIMALS; GENE THERAPY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856489651     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.215     Document Type: Review

References (10)

1. Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453 (2005). (Pubitemid 40313335)
2. Vincenti, F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535-546 (2010).
3. Vincenti, F. et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. http://dx.doi.org/10.1111/j.1600-6143.2011.03785.x.
4. Montgomery, R. A. et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365, 318-326 (2011).
5. Friedman, D. J., Kozlitina, J., Genovese, G., Jog, P. &Pollak, M. R. Population-based risk assessment of APOL1 on renal disease. J. Am. Soc. Nephrol. 22, 2098-2105 (2011).
6. Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 11, 1025-1030 (2011).
7. Newell, K. A. et al. for the Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836-1847 (2010).
8. Lozano, J. J. et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am. J. Transplant. 11, 1916-1926 (2011).
9. Merion, R. M. et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 294, 2726-2733 (2005). (Pubitemid 41770102)
10. Kayler, L. K., Srinivas, T. R. & Schold, J. D. Influence of CIT-induced DGF on kidney transplant outcomes. Am. J. Transplant. 11, 2657-2664 (2011).